ESMO

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Page 3 of 3
Results 21 - 23 of 23